This Week's HealthTech Earnings Report: Open Before Tomorrow
May 15th, 2022 (Earnings Report)Dear Reader,HealthTechMovers.com just identified several healthtech stocks that are expected to release earnings this week.If you are interested in any of these companies, we encourage you to do your own research and due diligence before pursuing any investments.Keep in mind, the actual earnings date and time may change, so if you’re interested in any of these companies you will need to pay close attention to their announcements.
Albireo Pharma
Symbol: ALBO
Recent Price: $$28
Average Analyst Price Target: $74.75 (166.96%)
Last Year's EPS: -$2.29
Consensus EPS Forecast: -$2.03
Expected Earnings Date: May 15 2022
Recent Analyst Action: Andreas Argyrides, analyst at Wedbush, reiterates coverage on Albireo Pharma (ALBO) in the Healthcare sector with a Buy rating and a price target of $ 75 (1 month ago).
TipRanks.com also reports that Albireo Pharma currently has 5 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $74.75 . The target pricing ranges from a high forecast of $80.00 down to a low forecast of $72.00. Albireo Pharma (ALBO)’s last closing price was $$28 which would put the average price target at 166.96% upside.Click for complete article >>
--------------------------------------------------------------------------
ATAI Life Sciences
Symbol: ATAI
Recent Price: $$3.64
Average Analyst Price Target: $29.50 (710.44%)
Last Year's EPS: $0.01
Consensus EPS Forecast: -$0.25
Expected Earnings Date: May 15 2022
Recent Analyst Action: Patrick Trucchio, analyst at H.C. Wainwright, reiterates coverage on ATAI Life Sciences (ATAI) in the Healthcare sector with a Buy rating and a price target of $ 50 (1 month ago).
TipRanks.com also reports that ATAI Life Sciences currently has 4 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $29.50 . The target pricing ranges from a high forecast of $50.00 down to a low forecast of $9.00. ATAI Life Sciences (ATAI)’s last closing price was $$3.64 which would put the average price target at 710.44% upside.Click for complete article >>
--------------------------------------------------------------------------
Chimerix
Symbol: CMRX
Recent Price: $$4.24
Average Analyst Price Target: $19.33 (355.90%)
Last Year's EPS: -$1.21
Consensus EPS Forecast: -$0.33
Expected Earnings Date: May 15 2022
Recent Analyst Action: Edward White, analyst at H.C. Wainwright, reiterates coverage on Chimerix (CMRX) in the Healthcare sector with a Buy rating and a price target of $ 24 (1 month ago).
TipRanks.com also reports that Chimerix currently has 3 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $19.33 . The target pricing ranges from a high forecast of $24.00 down to a low forecast of $14.00. Chimerix (CMRX)’s last closing price was $$4.24 which would put the average price target at 355.90% upside.Click for complete article >>
--------------------------------------------------------------------------
Compugen
Symbol: CGEN
Recent Price: $$1.93
Average Analyst Price Target: $12.00 (521.76%)
Last Year's EPS: -$0.12
Consensus EPS Forecast: -$0.13
Expected Earnings Date: May 15 2022
Recent Analyst Action: Daina Graybosch, analyst at SVB Securities, reiterates coverage on Compugen (CGEN) in the Healthcare sector with a Buy rating and a price target of n/a (2 weeks ago).
TipRanks.com also reports that Compugen currently has 5 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $12.00 . The target pricing ranges from a high forecast of $14.00 down to a low forecast of $8.00. Compugen (CGEN)’s last closing price was $$1.93 which would put the average price target at 521.76% upside.Click for complete article >>
--------------------------------------------------------------------------
Hookipa Pharma
Symbol: HOOK
Recent Price: $$1.37
Average Analyst Price Target: $8.60 (527.74%)
Last Year's EPS: -$0.53
Consensus EPS Forecast: -$0.24
Expected Earnings Date: May 15 2022
Recent Analyst Action: Swayampakula Ramakanth, analyst at H.C. Wainwright, reiterates coverage on Hookipa Pharma (HOOK) in the Healthcare sector with a Buy rating and a price target of $ 8 (1 month ago).
TipRanks.com also reports that Hookipa Pharma currently has 5 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $8.60 . The target pricing ranges from a high forecast of $16.00 down to a low forecast of $4.00. Hookipa Pharma (HOOK)’s last closing price was $$1.37 which would put the average price target at 527.74% upside.Click for complete article >>
--------------------------------------------------------------------------
Mind Medicine
Symbol: MNMD
Recent Price: $$0.78
Average Analyst Price Target: $6.76 (767.26%)
Last Year's EPS: -$0.04
Consensus EPS Forecast: -$0.05
Expected Earnings Date: May 15 2022
Recent Analyst Action: Patrick Trucchio, analyst at H.C. Wainwright, reiterates coverage on Mind Medicine (MNMD) in the Healthcare sector with a Buy rating and a price target of $ 10 (5 days ago).
TipRanks.com also reports that Mind Medicine currently has 3 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $6.76 . The target pricing ranges from a high forecast of $10.00 down to a low forecast of $3.29. Mind Medicine (MNMD)’s last closing price was $$0.78 which would put the average price target at 767.26% upside.Click for complete article >>
--------------------------------------------------------------------------
Novan
Symbol: NOVN
Recent Price: $$2.39
Average Analyst Price Target: $23.67 (890.38%)
Last Year's EPS: -$0.6
Consensus EPS Forecast: -$0.61
Expected Earnings Date: May 15 2022
Recent Analyst Action: Kemp Dolliver, analyst at Brookline Capital Markets, reiterates coverage on Novan (NOVN) in the Healthcare sector with a Buy rating and a price target of $ 17 (3 weeks ago).
TipRanks.com also reports that Novan currently has 3 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $23.67 . The target pricing ranges from a high forecast of $30.00 down to a low forecast of $17.00. Novan (NOVN)’s last closing price was $$2.39 which would put the average price target at 890.38% upside.Click for complete article >>
--------------------------------------------------------------------------
Pear Therapeutics
Symbol: PEAR
Recent Price: $$4.13
Average Analyst Price Target: $12.00 (190.56%)
Last Year's EPS: -$2.12
Consensus EPS Forecast: -$0.24
Expected Earnings Date: May 15 2022
Recent Analyst Action: Marie Thibault, analyst at BTIG, reiterates coverage on Pear Therapeutics (PEAR) in the Healthcare sector with a Buy rating and a price target of $ 12 (1 month ago).
TipRanks.com also reports that Pear Therapeutics currently has 4 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $12.00 . The target pricing ranges from a high forecast of $12.00 down to a low forecast of $12.00. Pear Therapeutics (PEAR)’s last closing price was $$4.13 which would put the average price target at 190.56% upside.Click for complete article >>
--------------------------------------------------------------------------
Quipt Home Medical
Symbol: QIPT
Recent Price: $$4.27
Average Analyst Price Target: $9.86 (130.83%)
Last Year's EPS: -$0.33
Consensus EPS Forecast: <$0.01
Expected Earnings Date: May 15 2022
Recent Analyst Action: Justin Keywood, analyst at Stifel Nicolaus, reiterates coverage on Quipt Home Medical (QIPT) in the Healthcare sector with a Buy rating and a price target of n/a (6 days ago).
TipRanks.com also reports that Quipt Home Medical currently has 3 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $9.86 . The target pricing ranges from a high forecast of $11.00 down to a low forecast of $8.72. Quipt Home Medical (QIPT)’s last closing price was $$4.27 which would put the average price target at 130.83% upside.Click for complete article >>
--------------------------------------------------------------------------
To Your Financial Future,
The Editor, HealthTechMovers.com